Article

Cardiovascular disease linked with inflammatory arthritis

Patients who have inflammatory arthritis and receive care from general practitioners have an almost 2-fold increased risk of prevalent cardiovascular disease (CVD) compared with those who do not. Therefore, assessing CVD risk and using prevention strategies in every patient who has inflammatory arthritis is important.

Patients who have inflammatory arthritis and receive care from general practitioners have an almost 2-fold increased risk of prevalent cardiovascular disease (CVD) compared with those who do not. Therefore, assessing CVD risk and using prevention strategies in every patient who has inflammatory arthritis is important.

Peters and colleagues compared the incidence of CVD in persons with inflammatory arthritis with that in healthy controls. They reviewed electronic medical records from 360,000 patients cared for at 96 general practices in the Netherlands, selecting persons who were 50 to 75 years old. Data included information on consultations, morbidity, prescriptions, and referrals to other health care professionals.

The prevalence of CVD was 66.1 per 1000 in patients with inflammatory arthritis and 37.3 per 1000 patients in the control group. Prevalences were found to be higher for patients with inflammatory arthritis in all age and sex strata, except in 60- to 64-year-old men and women. The odds ratios were 1.57 for myocardial infarction, 2.13 for transient ischemic attack, and 1.72 for stroke/cerebrovascular events; they tended to be higher for women with inflammatory arthritis than for men.

The authors noted that more research is warranted to better understand mechanisms that lead to the increased cardiovascular burden in this patient population.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.